Abstract:Aims While variants in KCNQ1 are the commonest cause of the congenital long QT syndrome, we and others find only a small IKs in cardiomyocytes from human induced pluripotent stem cells (iPSC-CMs) or human ventricular myocytes. Methods and Results We studied population control iPSC-CMs and iPSC-CMs from a patient with Jervell and Lange-Nielsen (JLN) syndrome due to compound heterozygous loss of function KCNQ1 variants. We compared the effects of pharmacologic IKs block to those of genetic KCNQ1 ablation, using JLN cells, cells homozygous for the KCNQ1 loss of function allele G643S, or siRNAs reducing KCNQ1 expression. We also studied the effects of two blockers of IKr, the other major cardiac repolarizing current, in the setting of pharmacologic or genetic ablation of KCNQ1: moxifloxacin, associated with a very low risk of drug-induced long QT, and dofetilide, a high-risk drug. In control cells, a small IKs was readily recorded but pharmacologic IKs block produced no change in action potential duration at 90% repolarization (APD90). By contrast, in cells with genetic ablation of KCNQ1 (JLN), baseline APD90 was markedly prolonged compared with control cells (469 ± 20 vs. 310 ± 16 ms). JLN cells displayed increased sensitivity to acute IKr block: the concentration (μM) of moxifloxacin required to prolong APD90 100 msec was 237.4 (median, IQR 100.6-391.6, n = 7) in population cells versus 23.7 (17.3-28.7, n = 11) in JLN cells. In control cells, chronic moxifloxacin exposure (300μM) mildly prolonged APD90 (10%) and increased IKs, while chronic exposure to dofetilide (5 nM) produced greater prolongation (67%) and no increase in IKs. However, in the siRNA-treated cells, moxifloxacin did not increase IKs, and markedly prolonged APD90. Conclusion Our data strongly suggest that KCNQ1 expression modulates baseline cardiac repolarization, and the response to IKr block, through mechanisms beyond simply generating IKs. Translational Perspective Mutations in KCNQ1 – whose expression generates IKs – are the major cause of long QT syndrome. We report here that while pharmacologic IKs block in human cardiomyocytes generates minimal change in repolarization, suppressing KCNQ1 expression markedly increases both baseline repolarization duration and sensitivity to some (but not all) specific IKr blockers. Thus, beyond simply generating IKs, KCNQ1 subserves critical additional role(s) in repolarization control at baseline and in response to IKr block. Our findings imply that assessment of arrhythmic risk in individual patients and by drugs requires a framework that extends beyond a simple one gene-one ion current paradigm.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the role of the KCNQ1 gene in the process of cardiac repolarization, especially whether its role is only limited to generating the IKs current. Specifically, the researchers observed that in human - induced pluripotent stem cell - derived cardiomyocytes (iPSC - CMs) or human ventricular myocytes, KCNQ1 variants are the most common cause of congenital long QT syndrome, but the IKs current in these cells is very small. This is in contradiction to the fact that KCNQ1 variants lead to long QT syndrome. Therefore, this study aims to explore whether KCNQ1 expression affects cardiac repolarization through other mechanisms and how this influence changes the sensitivity to IKr blockers. ### Research Background - The Kv7.1 channel encoded by **KCNQ1** is mainly responsible for generating the IKs current, while the hERG/Kv11.1 channel encoded by **KCNH2** is responsible for generating the IKr current. These two currents play a crucial role in the process of cardiac repolarization. - **Congenital long QT syndrome (cLQTS)** is a genetic disease, mainly caused by loss - of - function (LOF) variants of KCNQ1 or KCNH2, resulting in a prolonged cardiac repolarization time and an increased risk of arrhythmia. - **Drug - induced long QT syndrome (diLQT)** is usually caused by IKr blockers (such as dofetilide), and these drugs can significantly prolong the APD (action potential duration) and increase the risk of arrhythmia. ### Research Objectives - **Explore the influence of KCNQ1 expression on cardiac repolarization**: The researchers inhibited KCNQ1 expression through pharmacological and genetic methods and observed its influence on cardiac repolarization. - **Evaluate the influence of IKr blockers on cells with different KCNQ1 expression levels**: Compare the sensitivity of cells with different KCNQ1 expression levels to IKr blockers (such as moxifloxacin and dofetilide). ### Main Findings - **Pharmacological inhibition of IKs has a minor impact on repolarization**: After using the IKs - specific blocker HMR - 1556 to inhibit the IKs current, the APD90 of the control cells did not change much. - **Genetic inhibition of KCNQ1 leads to a significant prolongation of repolarization**: After inhibiting KCNQ1 expression through genetic methods (such as cells from JLN syndrome patients or siRNA treatment), the APD90 of the cells was significantly prolonged. - **Reduced KCNQ1 expression increases the sensitivity to IKr blockers**: Cells with reduced KCNQ1 expression showed a significantly increased sensitivity to IKr blockers (such as moxifloxacin), manifested as a significant prolongation of APD90. - **Moxifloxacin increases IKs, while dofetilide does not**: Chronic exposure to moxifloxacin can increase the IKs current, thereby partially offsetting the prolongation of APD90; while dofetilide does not have this effect. ### Conclusions - **KCNQ1 expression not only affects cardiac repolarization through generating IKs**: It may also affect cardiac repolarization through other mechanisms (such as regulating the function or transcriptional level of other ion channels). - **Evaluating the risk of arrhythmia requires considering multiple factors**: The single - gene - single - ion - current paradigm is not sufficient to comprehensively evaluate an individual's susceptibility to arrhythmia, and multiple factors need to be considered comprehensively. ### Translational Significance - **Evaluating the risk of arrhythmia**: This study suggests that when evaluating the risk of arrhythmia caused by drugs or genetic variants, the interaction of multiple ion channels needs to be considered, not just the change of a single gene. - **Personalized treatment**: Future research can further explore how to develop more personalized treatment plans according to an individual's genotype and phenotype to reduce the risk of arrhythmia. Through these findings, the researchers hope to provide a new perspective for understanding the mechanism of cardiac repolarization and more targeted strategies for clinical treatment.

The electrophysiologic effects of KCNQ1 extend beyond expression of I Ks: evidence from genetic and pharmacologic block

Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome

KCNQ1 Gain-of-function Mutation in Familial Atrial Fibrillation

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Identification of a KCNE2 Gain-of-Function Mutation in Patients with Familial Atrial Fibrillation

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

A Molecular Mechanism for Adrenergic-Induced Long QT Syndrome.

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events

Electrophysiological Characterization Reveals a Complex Phenotype Affecting the Slow Delayed Rectifier Potassium Current (IKs) Voltage Dependence by Causing a Hyperpolarizing Shift and a Lack of Response to Protein Kinase A Activation

The fully activated open state of KCNQ1 controls the cardiac 'fight-or-flight' response

Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

Targeting the IKs Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants

A Weak Dominant Negative Mutation of KCNQ1-G269S Affects PKA-Mediated Up-Regulation of IKs Channels and Causes Adrenergic Triggered Long QT Syndrome

Development of a Patient-Specific P.d85n-Potassium Voltage-Gated Channel Subfamily E Member 1–induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Suppression-Replacement Kcnq1 Gene Therapy For Type 1 Long Qt Syndrome

Functional regulation of Kv4.3 by 157T and V65M, two kinds of LQT6 associated mutations in KCNE2

Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel.

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

Abstract 13049: Electrophysiological Mechanism of Potassium Channel KCNQ1 p.V162M Mutation Induced Atrial Tachycardia and Epilepsy